

# **Selective α<sub>1</sub>-blockers Quinazoline derivatives( α<sub>1</sub>-blockers)**



very important for α1-receptor affinity

they block α1 receptor selectively, without blocking α2 receptor they produce peripherial vasodilation without increase in the heart rate.



### Tamsulosin


nonquinazoline benzsulfonamide

more selective for  $\alpha 1A$ -receptors than for the other  $\alpha 1$ -receptors blockade of  $\alpha 1A$ -receptors found in the prostate gland over those found in vascular tissue. treatment of BPH with little effect on blood pressure. Orthostatic hypotension is not as great with this agent as with the nonselective quinazolines

#### Selective $\alpha$ 2-blockers


### Example •Indol alkaloide

These isomeric indol alkaloide known as yohimbine and corynanthine exhibited different degree of selectivity toward α1 and α2 receptors depending on the stereochemistry.




Yohimbine selective α2-receptor carbomethoxy in plan of alkaloid ring

increases heart rate and blood pressure as a result of its blockade of α2-receptors in the CNS. It has been used experimentally to treat male erectile impotence.



Corynanthine selective α1-receptor carbomethoxy out of plan of alkaloid ring (axial)

# 2-Mirtazapine (Remeron)



selective  $\alpha$ 2-receptors versus  $\alpha$ 1-receptors

Blockade of central  $\alpha$ 2-receptors results in an increased release of NE and serotonin antidepressant.

This agent also has activity at nonadrenergic receptors.

It is a potent blocker of 5-HT2 and 5-HT3 serotonin receptors


and at histamine H1-receptors.

### **β-Blockers**


### Structure activity relationship

β-Blockers are among the most widely employed antihypertensives and are also considered the first-line treatment for glaucoma.


Most of  $\beta$ -blockers are in the chemical class of aryloxypropanolamines



## B-blocker (Aryloxypropanolamine) <u>SAR</u>




The nature of the aromatic  $\rightarrow \beta$ 1-selectivity of the antagonist presence of a para-substituent of sufficient size along with the absence of meta-substituents.



# Practolol (a prototype of β1 blocker) cause several toxic effect so no longer use


## NONSELECTIVE β-BLOCKERS (FIRST GENERATION) •Propranolol (Inderal)




competitive blocking agent (receptor-blocking actions can be reversed with sufficient concentrations of β-agonists)

# propranolol is approved for use in the United States for:-


- Hypertension.
- Cardiac arrhythmias.
- Angina pectoris.
- Post myocardial infarction.
- Hypertrophic cardiomyopathy.
- Pheochromocytoma.,
- Migraine prophylaxis.
- •Essential tremor.




Nadolol Antihypertensive angina pectoris longer DOA(20 hrs)



Sotalol Antiarrythmias only phenyl ethyamine





Penbutolol Antihypertensive posses partial agonist activity→ cause less slowing of the resting heart rate (brady cardia)


## Selective β 1- blockers (Second generation(

 $\beta_1$ -blockers are drugs that have a greater affinity for the  $\beta_{-1}$  receptors of the heart than for  $\beta_2$ -receptors in other tissues .


Such cardioselective agents should provide two important therapeutic advantages

•Should be the lack of a blocking effect on the  $\beta_2$ -receptors in the bronchi (safe for use in patients who have bronchitis or bronchial asthma.(


•Should be the absence of blockade of the vascular  $\beta_2$ -receptors, which mediate vasodilation. This would be expected to reduce or eliminate the increase in peripheral resistance that sometimes occurs after the administration of nonselective  $\beta$ -blockers . Note:- Unfortunately, cardioselectivity is usually observed with  $\beta_1$ -blockers at only relatively low doses. At normal therapeutic doses, much of the selectivity is lost.









Betaxolol Antihypertensive antiglucoma half-life 14-22hrs→ longer DOA



Atenolol Antihypertensive angina pectoris Atenolol (log P = 0.10), →low lipid solubility → does not readily cross the BBB. It is absorbed incompletely from the gastrointestinal tract, the oral bioavailability being approximately 50%.




Esmolol Antihypertensive and cardiac arrythemias half-life 9 min→ short DOA→rapid hydrolysis by esterase weak β-blockers and not exhibit clinically significant effects administered by continous IV infusion for control ventricular rate in patient with atrial flutter, atrial fibrillation, or sinus tachycardia



a selective  $\beta$ 1-blocker with partial agonistic activity has a longer half-life (8-12 hours) than the parent drug and is excreted by the kidneys <u>β-bl ockers with *a*<sub>1</sub>-antagonist activity (third generation)</u>

**1- Labetalol** 



#### Labetalol

phenylethanolamine derivative

competitive blockers at  $\alpha 1$ -,  $\beta 1$ -, and  $\beta 2$ -receptors


It is a more potent  $\beta$ -blocker than  $\alpha$ -blocker

used as antihypertensive

Because it has two asymmetric carbon atoms (1 and 1'), it exists as a mixture of four isomers.

The different isomers, possess different  $\beta$ - and  $\alpha$ -blocking activities

# 2- Carvedilol



Carvedilol\* β-blocker and α-blocker Only the (S) enantiomer possesses theβ-blocking activity both enantiomers are blockers of the α1-receptor β-blocking activity is 10- to 100-fold of its α-blocking activity possesses antioxidant activity and an antiproliferative effect on vascular smooth muscle cells used in treating hypertension and congestive heart failure.